

1 **WO**

2  
3  
4  
5  
6 **IN THE UNITED STATES DISTRICT COURT**  
7 **FOR THE DISTRICT OF ARIZONA**

8  
9 Richard Di Donato, individually and on  
behalf of all others similarly situated,

10 **Plaintiff,**

11 v.

12 Insys Therapeutics, Inc.; Michael L.  
13 Babich; Darryl S. Baker; John N. Kapoor;  
and Alec Burlakoff,

14 **Defendants.**

No. CV-16-00302-PHX-NVW

**ORDER**

15  
16  
17 Before the Court are Lead Plaintiff's Motion for Class Certification (Doc. 159) and  
18 Defendants' Motion for Leave to File Sur-Reply in Further Opposition to Lead Plaintiff's  
19 Motion for Class Certification (Doc. 170).

20 On June 10, 2019, Defendant Insys Therapeutics Inc. ("Insys") commenced a  
21 voluntary case under chapter 11 of title 11 of the United States Code (11 U.S.C. § 101 *et*  
22 *seq.*) in the United States Bankruptcy Court for the District of Delaware, and this action is  
23 automatically stayed with respect to Insys. (Doc. 230.) This action is not stayed as to the  
24 proceedings against the Defendants other than Insys. (Doc. 258.) This Order, therefore,  
25 applies only to Defendants Michael L. Babich, Darryl S. Baker, and John N. Kapoor.  
26 Claims against Defendant Alec Burlakoff were dismissed. (Doc. 107 at 41.)  
27  
28

1 **I. BACKGROUND**

2 Insys is a publicly traded<sup>1</sup> pharmaceutical company headquartered in Arizona that  
3 makes and sells Subsys, a very expensive sublingual fentanyl spray approved by the Food  
4 and Drug Administration to treat breakthrough pain in adult cancer patients already taking  
5 opioid pain medication. Babich, Baker, and Kapoor served as high-level executives at  
6 Insys during 2014 through 2016. During that time, Insys reported increasing revenues each  
7 quarter and attributed most of its upward trajectory to the sale of Subsys. Insys touted its  
8 unique programs within the oncology setting for increasing sales and claimed that it was  
9 taking market share from competing products for breakthrough cancer pain by building  
10 awareness among oncologists. However, as alleged, Insys actively discouraged promoting  
11 Subsys for cancer patients, less than 1% of Subsys prescriptions were written by  
12 oncologists, and Insys paid doctors bribes and kickbacks in exchange for prescribing  
13 Subsys off-label.

14 Company executives publicly attributed the drug's success to vigorous marketing  
15 efforts and the company's diligent negotiations with pharmacy benefit managers, third-  
16 party payers, and insurers. Insys created an "Insurance Reimbursement Center,"  
17 sometimes called the "Prior Authorization Unit," ostensibly to interact with third-party  
18 payers to obtain prior authorization and insurance coverage for Subsys prescriptions.  
19 Employees of the "Insurance Reimbursement Center" allegedly falsified patient diagnoses,  
20 lied to insurance companies, and posed as employees of the prescribing doctors.

21 Plaintiff alleges that Defendants made the following materially false and misleading  
22 statements:

23 268. More specifically, Defendant Babich stated:

24 ***I think Q4 is a great indication of what we can do with the***  
25 ***product moving forward, as well.*** I think that is important for  
26 ***folks—our sales force expansion was based on opportunity.***  
27 ***We keep hitting new highs in the number of new doctors that***  
***we activate on a weekly basis. We have some very unique***

---

28 <sup>1</sup> During the Class Period, Insys common stock traded on the NASDAQ.

1 *programs within the oncology setting that we continue to*  
2 *execute on and any growth that we see in this overall TIRF*  
3 *class is specifically coming from Subsys.*

4 So we feel that this is our market to continue to grow and to  
5 continue to dominate, like we are doing at this point with our  
6 market share. I've always talked about, from a market share,  
7 our next total is 50% market share. You can see that in Q4 the  
8 Actiq generic continued to decline, so we continued to take  
9 market share from the generic. *And I think that's a testament*  
10 *to the fact that we have a clinically superior product to the*  
11 *Actiq generic out there.* So I think long term we can  
12 eventually get to that 60% market share for this product.

13 . . . .

14 272. Furthermore, with respect to the continued growth of Subsys,  
15 the FY14 Form 10-K also explained:

16 *some of the key factors in generating continued growth in*  
17 *Subsys usage include taking market share from other*  
18 *competing TIRF products and expanding the usage of Subsys*  
19 *for BTCP by building awareness among oncologists of its*  
20 *rapid onset of action, improved bioavailability, most complete*  
21 *range of dosage strengths and ease of administration relative*  
22 *to other TIRF products.*

23 (Doc. 77 at 103-05; *see* Doc. 107 at 41.) "TIRF" refers to "Transmucosal Immediate-  
24 Release Fentanyl." "BTCP" refers to "breakthrough cancer pain."

25 Plaintiff also alleges that Insys stock prices declined because of news or  
26 announcements to investors that revealed the company's prior statements to have been false  
27 or misleading. On November 4, 2015, CNBC published an article on its website revealing  
28 that the Department of Health and Human Services classified Subsys as commonly  
prescribed for unintended uses. In the context of publicized fraud allegations against Insys  
employees and collaborating healthcare providers, the article constituted a partial  
disclosure of the company's underlying fraud. On December 3, 2015, and January 25,  
2016, the Southern Investigative Reporting Foundation partially disclosed fraud by Insys  
in articles about the company's "Prior Authorization Unit" and Babich's resignation.

1 Plaintiff seeks to certify a class (the “Class”) pursuant to Federal Rules of Civil  
2 Procedure 23(a) and 23(b)(3) consisting of all persons and entities who purchased or  
3 otherwise acquired Insys common stock during the period from March 3, 2015, through  
4 January 25, 2016 (the “Class Period”), and were damaged thereby. Excluded from the  
5 Class are Defendants; present and former directors or executive officers of Insys and  
6 members of their immediate families; any of the foregoing individuals’ or entities’ legal  
7 representatives, heirs, successors, or assigns; and any entity in which any Defendant has or  
8 had a controlling interest or which is related to or affiliated with any Defendant.

9 Count I of Plaintiff’s Second Amended Complaint alleges against all Defendants  
10 securities fraud in violation of Section 10(b) of the Exchange Act, 15 U.S.C. § 78j(b), and  
11 Rule 10b-5 promulgated thereunder by the SEC, 17 C.F.R. § 240.10b-5. Count II alleges  
12 control-person liability for Defendants Babich, Baker, and Kapoor under Section 20(a) of  
13 the Exchange Act. (*See* Docs. 77, 107.)

## 14 **II. DEFENDANTS’ MOTION FOR LEAVE TO FILE SUR-REPLY**

15 Defendants move for leave to file a sur-reply to respond to arguments and evidence  
16 included for the first time in Plaintiff’s reply in support of his motion for class certification.  
17 (Doc. 170.) Defendants respond not only to “new” arguments and evidence included in  
18 Plaintiff’s reply, but also to issues that were “not addressed in any meaningful detail” in  
19 Plaintiff’s opening brief. Plaintiff contends that each of the arguments Defendants describe  
20 as “new” is a response to arguments or concessions Defendants did not make until they  
21 filed their response to the class certification motion or to Defendants’ attempt to rebut the  
22 presumption that proposed class members relied on Defendants’ misstatements.  
23 Defendants attached their proposed sur-reply to be filed if leave were granted. Plaintiff’s  
24 opposition brief responds both to the motion and the content of the proposed sur-reply.

25 Where new evidence is presented in a reply brief, the district court should not  
26 consider the new evidence without giving the non-movant an opportunity to respond.  
27 *Provenz v. Miller*, 102 F.3d 1478, 1483 (9th Cir. 1996). Here, both sides have addressed  
28 any “new” evidence and arguments presented in Plaintiff’s reply brief. Because Plaintiff

1 has responded to the content of Defendants’ proposed sur-reply, there is no prejudice or  
2 unfairness in allowing Defendants’ proposed sur-reply to be filed. In deciding Plaintiff’s  
3 motion for class certification, the Court considers both Defendants’ sur-reply and  
4 Plaintiff’s opposition brief along with all of the other related submissions.

5 **III. RULE 23(a)**

6 “A party seeking class certification must affirmatively demonstrate his compliance  
7 with [Federal Rule of Civil Procedure 23.]” *Wal-Mart Stores, Inc. v. Dukes*, 564 U.S. 338,  
8 350 (2011). The party must prove compliance with Rule 23 *in fact*. *Id.* “[C]ertification is  
9 proper only if the trial court is satisfied, after a rigorous analysis, that the prerequisites of  
10 Rule 23(a) have been satisfied.” *Id.* (internal quotation marks omitted). Although the class  
11 certification analysis might include some overlap with the merits of the plaintiff’s  
12 underlying claim, merits questions may be considered only to the extent that they are  
13 relevant to determining whether the Rule 23 prerequisites for class certification are  
14 satisfied. *Id.* at 351; *Amgen Inc. v. Connecticut Ret. Plans & Trust Funds*, 568 U.S. 455,  
15 466 (2013).

16 Under Rule 23(a), the party seeking certification must prove:

- 17 (1) the class is so numerous that joinder of all members is  
18 impracticable;
- 19 (2) there are questions of law or fact common to the class;
- 20 (3) the claims or defenses of the representative parties are typical  
21 of the claims or defenses of the class; and
- 22 (4) the representative parties will fairly and adequately protect the  
23 interests of the class.

24 Defendants do not dispute that the proposed class satisfies Rule 23(a).

25 Numerosity. Rule 23(a)’s numerosity requirement is generally assumed to have  
26 been met in class action suits involving nationally traded securities. *Zeidman v. J. Ray*  
27 *McDermott & Co.*, 651 F.2d 1030, 1039 (5th Cir. 1981); *see, e.g., In re Infineon Techs. AG*  
28 *Sec. Litig.*, 266 F.R.D. 386, 393 (N.D. Cal. 2009). “Joinder impracticability (numerosity)  
is rarely contested in class actions brought on behalf of shareholders or traders in publicly  
owned corporations. In class actions brought on behalf of securities traders, federal trial

1 courts are quite willing to accept common sense assumptions in order to support a finding  
2 of numerosity.” *Zeidman*, 651 F.2d at 1039 (quoting 5 J. Newburg, *Class Actions* § 8812,  
3 at 836 (1977)).

4 Plaintiff has submitted evidence, which Defendants do not dispute, that during the  
5 Class Period there were between 70 and 72 million shares of Insys common stock  
6 outstanding, an average of 4.5 million shares traded weekly, and at least 280 institutional  
7 investors held Insys common stock. This satisfies Rule 23(a)(1).

8 Commonality. To demonstrate “questions of law or fact common to the class,”  
9 plaintiffs’ claims must depend on a common contention capable of classwide resolution  
10 such that determination of the truth of the contention will resolve an issue central to the  
11 validity of each of the claims. *Wal-Mart*, 564 U.S. at 350. Plaintiff has identified numerous  
12 common questions of law and fact, which include whether Defendants’ statements  
13 misrepresented or omitted facts, whether Defendants’ statements created and/or maintained  
14 artificial inflation in the price of Insys common stock, and whether alleged stock price  
15 declines are causally connected to Defendants’ misrepresentations and omissions. This  
16 satisfies Rule 23(a)(2).

17 Typicality. The typicality requirement ensures that the interest of the class  
18 representative aligns with the interests of the class. *Just Film, Inc. v. Buono*, 847 F.3d  
19 1108, 1116 (9th Cir. 2017). Indicators of typicality include whether other members have  
20 the same or similar injury, whether the action is based on conduct that is not unique to the  
21 named plaintiffs, and whether other class members have been injured by the same course  
22 of conduct. *Id.* “Under the rule’s permissive standards, representative claims are ‘typical’  
23 if they are reasonably co-extensive with those of absent class members; they need not be  
24 substantially identical.” *Hanlon v. Chrysler Corp.*, 150 F.3d 1011, 1020 (9th Cir. 1998).

25 The proposed class consists of all persons and entities who purchased or otherwise  
26 acquired Insys common stock during the Class Period and were damaged thereby. Plaintiff,  
27 like the other members of the proposed class, purchased Insys common stock during the  
28 Class Period at prices that Plaintiff alleges were artificially inflated by Defendants’

1 materially false or misleading statements and allegedly suffered damages when the  
2 concealed truth was revealed, causing the stock price to decline. This satisfies Rule  
3 23(a)(3).

4 Adequacy of Plaintiff and Class Counsel. The final requirement for class  
5 certification under Rule 23(a) is that “the representative parties will fairly and adequately  
6 protect the interests of the class.” “Resolution of two questions determines legal adequacy:  
7 (1) do the named plaintiffs and their counsel have any conflicts of interest with other class  
8 members and (2) will the named plaintiffs and their counsel prosecute the action vigorously  
9 on behalf of the class?” *Hanlon*, 150 F.3d at 1020.

10 Plaintiff has certified that he is willing to serve as a representative party on behalf  
11 of the class, including providing testimony at deposition and trial, if necessary. (Doc.  
12 34-1.) He further certified that he will not accept any payment for serving as a  
13 representative party on behalf of the class beyond his pro rata share of any recovery, except  
14 directly related reasonable costs and expenses as ordered by the Court. He disclosed his  
15 Class Period purchase and sale transactions in Insys securities that are the subject of this  
16 action. Plaintiff submitted information regarding the qualifications of Kessler Topaz  
17 Meltzer & Check, LLC, to serve as Class Counsel and those of Bonnett, Fairbourn,  
18 Friedman & Balint, P.C., to serve as Liaison Counsel under Rule 23(g). Defendants do not  
19 dispute that Plaintiff and his counsel will fairly and adequately protect the interests of the  
20 class.

21 Defendants do not dispute that the proposed class satisfies Rule 23(a).

22 **IV. RULE 23(b)**

23 In addition to satisfying Rule 23(a), the proposed class must satisfy at least one of  
24 the three requirements stated in Rule 23(b). Plaintiff relies on Rule 23(b)(3), which  
25 requires findings regarding both predominance and superiority:

26 The court finds that the questions of law or fact common to class members  
27 predominate over any questions affecting only individual members, and that  
28 a class action is superior to other available methods for fairly and efficiently  
adjudicating the controversy. The matters pertinent to these findings include:



1 (A) the class members' interests in individually controlling the  
prosecution or defense of separate actions;

2 (B) the extent and nature of any litigation concerning the controversy  
3 already begun by or against class members;

4 (C) the desirability or undesirability of concentrating the litigation of  
5 the claims in the particular forum; and

6 (D) the likely difficulties in managing a class action.

7 Defendants do not dispute that Plaintiff has shown that a class action is superior to other  
8 available methods for fairly and efficiently adjudicating the controversy presented in this  
9 case.

10 The only remaining decision is whether "the questions of law or fact common to  
11 class members predominate over any questions affecting only individual members."

12 Considering whether "questions of law or fact common to class members  
13 predominate" begins, of course, with the elements of the underlying cause of  
14 action. The elements of a private securities fraud claim based on violations  
15 of § 10(b) and Rule 10b-5 are: (1) a material misrepresentation or omission  
16 by the defendant; (2) scienter; (3) a connection between the  
misrepresentation or omission and the purchase or sale of a security; (4)  
reliance upon the misrepresentation or omission; (5) economic loss; and (6)  
loss causation.

17 *Erica P. John Fund, Inc. v. Halliburton Co.* ("Halliburton I"), 563 U.S. 804, 809-10 (2011)  
18 (internal quotation marks and citations omitted). Defendants contend that Plaintiff cannot  
19 satisfy Rule 23(b)'s predominance requirement with respect to the questions of reliance  
20 and damages.

21 Although reliance by the plaintiff on the defendant's deceptive acts is an essential  
22 element of the § 10(b) private cause of action, limiting proof of reliance to showing that  
23 the plaintiff was aware of a company's statement and engaged in a relevant transaction  
24 based on that specific misrepresentation "would place an unnecessarily unrealistic  
25 evidentiary burden on the Rule 10b-5 plaintiff who has traded on an impersonal market."  
26 *Id.* at 810 (quoting *Basic Inc. v. Levinson*, 485 U.S. 224, 245 (1988)). Moreover, requiring  
27 proof of individualized reliance would effectively prevent plaintiffs from proceeding with  
28 a class action because individual issues would overwhelm the common ones. *Id.*



1 Therefore, in *Basic*, the Court permitted plaintiffs to invoke a rebuttable presumption of  
2 reliance based on the “fraud-on-the-market” theory. *Id.*

3 **A. The Fraud-on-the-Market Rebuttable Presumption of Reliance**

4 The *Basic* rebuttable presumption of reliance is based on the theory that the market  
5 price of shares traded on well-developed markets reflects all publicly available  
6 information, including material misrepresentations. *Id.* at 811. It is assumed that an  
7 investor relies on public misstatements whenever he buys or sells stock at market prices.  
8 *Id.*

9 This presumption springs from the very concept of market efficiency. If a  
10 market is generally efficient in incorporating publicly available information  
11 into a security’s market price, it is reasonable to presume that a particular  
12 public, material misrepresentation will be reflected in the security’s price.  
13 Furthermore, it is reasonable to presume that most investors—knowing that  
14 they have little hope of outperforming the market in the long run based solely  
15 on their analysis of publicly available information—will rely on the  
16 security’s market price as an unbiased assessment of the security’s value in  
17 light of all public information. Thus, courts may presume that investors  
18 trading in efficient markets indirectly rely on public, material  
19 misrepresentations through their reliance on the integrity of the price set by  
20 the market.

21 *Amgen Inc. v. Connecticut Ret. Plans & Trust Funds*, 568 U.S. 455, 462 (2013). The fraud-  
22 on-the-market presumption can be rebutted by appropriate evidence. *Halliburton I*, 563  
23 U.S. at 811. “Any showing that severs the link between the alleged misrepresentation and  
24 either the price received (or paid) by the plaintiff, or his decision to trade at a fair market  
25 price, will be sufficient to rebut the presumption of reliance.” *Basic*, 485 U.S. at 248.  
26 However,

27 *Basic*’s presumption of reliance . . . does not rest on a ‘binary’ view of market  
28 efficiency. Indeed, in making the presumption rebuttable, *Basic* recognized  
that market efficiency is a matter of degree and accordingly made it a matter  
of proof.

. . . Even the foremost critics of the efficient-capital-markets hypothesis  
acknowledge that public information generally affects stock prices. . . .  
Debates about the precise *degree* to which stock prices accurately reflect  
public information are thus largely beside the point.

1 *Erica P. John Fund, Inc. v. Halliburton Co.* (“*Halliburton II*”), 573 U.S. 258, 272 (2014).

2 *Basic*’s fraud-on-the-market presumption does not relieve plaintiffs of the burden  
3 of proving, not simply pleading, the predominance requirement of Rule 23(b)(3) before  
4 class certification. *Id.* at 276. To demonstrate that the presumption of reliance applies, a  
5 plaintiff must prove: “(1) the alleged misrepresentations were publicly known, (2) they  
6 were material, (3) the stock traded in an efficient market, and (4) the plaintiff traded the  
7 stock between when the misrepresentations were made and when the truth was revealed.”  
8 *Id.* at 277-78. The first three prerequisites are directed at whether the alleged  
9 misrepresentations affected the market price, *i.e.*, price impact. *Id.* at 278. Plaintiffs are  
10 not required to prove price impact directly; such a requirement would eliminate the  
11 presumption that a misrepresentation affected the stock price. *Id.* at 279.

12 Defendants may defeat the fraud-on-the-market presumption of reliance at the class  
13 certification stage with evidence that the misrepresentation in fact did not affect the stock  
14 price. *Id.* Defendants may introduce price impact evidence at the class certification stage,  
15 but only “for the purpose of countering a plaintiff’s showing of market efficiency, rather  
16 than directly rebutting the presumption.” *Id.* at 280. While *Basic* allows plaintiffs to  
17 establish price impact indirectly, “it does not require courts to ignore a defendant’s direct,  
18 more salient evidence showing that the alleged misrepresentation did not actually affect  
19 the stock market’s price and, consequently, that the *Basic* presumption does not apply.”  
20 *Id.* at 282.

21 Although materiality is an essential predicate of the fraud-on-the-market theory,  
22 Rule 23(b) does not require a plaintiff invoking the fraud-on-the-market presumption of  
23 reliance to prove materiality at the class certification stage because such proof is not  
24 necessary to ensure satisfaction of the predominance requirement. *Amgen*, 568 U.S. at 466,  
25 467 & n.4. Materiality is a common question for purposes of Rule 23(b)(3), and failure of  
26 proof on that common question will not result in individual questions predominating. *Id.*  
27 at 467-68.

28

### 1. Factors that Demonstrate Market Efficiency

1 Defendants contend that Plaintiff is not entitled to presumption of reliance based on  
2 the fraud-on-the-market theory because he has not shown that the market is efficient. To  
3 determine whether a market is efficient, *i.e.*, whether stock prices reflect public  
4 information, the Ninth Circuit and many other courts have considered five characteristics  
5 of the company and its stock (referred to as the *Cammer* factors): (1) whether the stock  
6 trades at a high weekly volume; (2) whether securities analysts follow and report on the  
7 stock; (3) whether the stock has market makers and arbitrageurs; (4) whether the company  
8 is eligible to file SEC registration form S-3; and (5) whether there are “empirical facts  
9 showing a cause and effect relationship between unexpected corporate events or financial  
10 releases and an immediate response in the stock price.” *Binder v. Gillespie*, 184 F.3d 1059,  
11 1065 (9th Cir. 1999) (quoting *Cammer v. Bloom*, 711 F. Supp. 1264, 1286-87 (D.N.J.  
12 1989)). The fifth characteristic, empirical evidence of a causal relationship, “is the essence  
13 of an efficient market and the foundation for the fraud on the market theory.” *Cammer*,  
14 711 F. Supp. at 1287. “[I]n an efficient market, a stock’s price remains relatively stable in  
15 the absence of news, and changes very rapidly as the market receives new and unexpected  
16 information.” *Krogman v. Sterritt*, 202 F.R.D. 467, 474 (N.D. Tex. 2001).

17 Here, the parties dispute whether the fraud-on-the-market presumption requires  
18 plaintiffs to prove satisfaction of the fifth *Cammer* factor. Defendants do not dispute that  
19 the first four *Cammer* factors are satisfied here, but they contend that Plaintiff must meet,  
20 and has not met, his burden of proving the fifth *Cammer* factor. Plaintiff contends that he  
21 has done so and also that it is not necessary to prove the fifth *Cammer* factor where the  
22 first four factors are satisfied and additional factors demonstrate market efficiency.

23 The *Cammer* court stated that it is not logical to draw bright line tests to assist fact  
24 finders in determining whether a stock trades in an open and efficient market. *Cammer*,  
25 711 F. Supp. at 1287. The Ninth Circuit described the *Cammer* factors as “designed to  
26 help make the central determination of efficiency in a particular market.” *Binder*, 184 F.3d  
27 at 1065. In a different context, the Ninth Circuit described the *Cammer* factors as setting  
28

1 a necessarily “high bar” because “[d]ue process concerns require that class certification  
2 meet rigorous standards in securities cases.” *Miller v. Thane Int’l, Inc.*, 615 F.3d 1095,  
3 1103 (9th Cir. 2010). However, the only specific guidance from the Ninth Circuit is that  
4 evidence supporting only the third factor, the existence of market makers and arbitrageurs,  
5 is insufficient to invoke the presumption of reliance. *Binder*, 184 F.3d at 1065.

6 Some courts have held that the *Cammer* factors can be supplemented by other  
7 measures, such as the company’s market capitalization, the bid-ask spread, the issue  
8 amount outstanding excluding insider-owned securities, and the percentage of institutional  
9 ownership. *Petrie v. Electronic Game Card, Inc.*, 308 F.R.D. 336, 349 (C.D. Cal. 2015).  
10 Three of these factors are commonly referred to as the “*Krogman* factors”: “(1) the  
11 capitalization of the company; (2) the bid-ask spread of the stock; and (3) the percentage  
12 of stock not held by insiders (the ‘float’).” *Krogman v. Sterritt*, 202 F.R.D. 467, 474 (N.D.  
13 Tex. 2001). In *Krogman*, the court found two of the five *Cammer* factors weighed in favor  
14 of market efficiency, and two weighed against; regarding the fifth factor, the relationship  
15 of price changes to news was “inconsistent at best.” *Id.* at 477. Of the three additional  
16 factors, one weighed slightly in favor of a determination of market efficiency, and two did  
17 not. *Id.* at 478. The court concluded that the presumption of reliance did not apply.

18 The Second, Fourth, Fifth, and Eleventh Circuits have instructed that the *Cammer*  
19 factors serve only as a guide for determining market efficiency to be applied in a case-by-  
20 case basis in addition to other considerations and that, while important in certain cases, the  
21 fifth *Cammer* factor is not a mandatory prerequisite in every case for finding market  
22 efficiency. *Waggoner v. Barclays PLC*, 875 F.3d 79, 97-98 (2d Cir. 2017); *Gariety v.*  
23 *Grant Thornton, LLP*, 368 F.3d 356, 368 (4th Cir. 2004); *Unger v. Amedisys Inc.*, 401 F.3d  
24 316, 323 (5th Cir. 2005); *Bell v. Ascendant Solutions, Inc.*, 422 F.3d 307, 313, 316 (5th  
25 Cir. 2005); *Local 703, I.B. of T. Grocery & Food Employees Welfare Fund v. Regions*  
26 *Financial Corp.*, 762 F.3d 1248, 1255-56 (11th Cir. 2014). Although these circuit courts  
27 require proof and thorough analysis of market efficiency in context, they disclaim rigid  
28

1 adherence to a bright line test. The parties have not cited, and the Court has not found,  
2 contrary authority.

3 In *Regions*, the Eleventh Circuit concluded that it was not wise to require district  
4 courts to analyze market efficiency in terms of the *Cammer* factors in every case and better  
5 to allow district courts flexibility to perform the analysis “in the most sensible way given  
6 the circumstances.” 762 F.3d at 1256. Specifically, the Eleventh Circuit stated that a  
7 finding of market efficiency does not always require proof that the alleged  
8 misrepresentations had an immediate effect on the stock price. For example, when a  
9 company releases expected information, regardless of whether it is truthful, the theory  
10 underlying the fraud-on-the-market presumption predicts that the disclosure will cause no  
11 significant change in the stock price. Further,

12 Neither would it make sense to impose an unwavering requirement for  
13 plaintiffs to identify unexpected disclosures during or around the class period  
14 that had an immediate price impact. In any given case there may be no  
15 unexpected disclosures during the period at all, because the company is  
16 withholding that information. To require plaintiffs to prove a set number of  
17 unexpected disclosures resulting in an immediate price impact would rob  
18 District Courts of the flexibility they need to conduct holistic, fact-sensitive  
19 inquiries into the efficiency of the market for the particular stock before it.

20 *Id.* at 1257. In *Regions*, the Eleventh Circuit affirmed the district court’s finding that the  
21 presumption of classwide reliance was justified and remanded for the district court to  
22 determine whether the presumption had been rebutted.

23 Similarly, the Second Circuit said that the fifth *Cammer* factor might be the most  
24 important factor in certain cases, such as when the other *Cammer* and/or *Krogman* factors  
25 are less compelling, but a plaintiff need not always present direct evidence of price impact  
26 through event studies to demonstrate market efficiency. *Waggoner*, 875 F.3d at 97-98. In  
27 *Waggoner*, the first four *Cammer* factors and the three *Krogman* factors weighed so clearly  
28 in favor of concluding that the market was efficient that the defendants did not even  
challenge them. Thus, the district court’s decision not to rely on direct evidence of price  
impact under the fifth *Cammer* factor fell within its discretion. *Id.* at 98.

1           In *Unger*, the Fifth Circuit said the five *Cammer* factors and the three *Krogman*  
2 factors do not represent an exhaustive list of factors to be considered in determining market  
3 efficiency, and in some cases one of those factors might be unnecessary. 401 F.3d at 323.  
4 But the factors “must be weighed analytically, not merely counted, as each of them  
5 represents a distinct facet of market efficiency.” *Id.* The Fifth Circuit held that the district  
6 court devoted insufficient attention to evaluating the market efficiency factors. The district  
7 court had found a high stock trading volume, but the plaintiffs never proved the actual  
8 number of shares being regularly traded. The district court had relied on the number of  
9 market makers with no further analysis. And the district court had found a causal  
10 connection between corporate events and movement of the stock price, but it did not take  
11 into account the many other factors that could affect the price of the stock. Moreover, the  
12 district court failed to evaluate the significance of the factors that were lacking.

13           In *Bell*, the Fifth Circuit affirmed both the district court’s exclusion of expert  
14 testimony regarding market efficiency found to be unreliable and its denial of class  
15 certification. 422 F.3d at 316. The plaintiffs did not provide any analysis of market  
16 efficiency factors except for the excluded expert testimony, and there was insufficient  
17 evidence to support finding the market was efficient. The appellate court found no abuse  
18 of discretion in denying class certification where the plaintiffs’ expert report was excluded,  
19 the plaintiffs’ briefing to the district court was “devoid of any serious effort to show market  
20 efficiency,” and the plaintiffs bore the burden of proof. *Id.*

21           In summary, Plaintiff bears the burden of proving market efficiency required for  
22 application of the fraud-on-the-market presumption of reliance. There is no bright line test  
23 for market efficiency. The Court may consider evidence related to the *Cammer* factors,  
24 the *Krogman* factors, and/or any other market characteristics relevant to a specific case.  
25 The factors provide a framework for thorough analysis, not a checklist for keeping score.  
26 Evidence of the market’s reaction to unexpected corporate events or financial disclosures  
27 is usually important, but not required in every case.

28

## 2. Evidence Regarding the Fifth *Cammer* Factor

1 Defendants do not dispute that Plaintiff has shown sufficient evidence of the first  
2 four *Cammer* factors. They contend only that Plaintiff has not established the fifth factor,  
3 which is whether there are “empirical facts showing a cause and effect relationship between  
4 unexpected corporate events or financial releases and an immediate response in the stock  
5 price.” *Cammer*, 711 F. Supp. at 1287.  
6

7 Plaintiff has submitted evidence that during the Class Period Insys common stock  
8 had a high weekly trading volume, significant analyst coverage, and 97 market makers.  
9 Plaintiff’s expert, Chad Coffman, CFA, found no evidence that Insys was not eligible to  
10 file a SEC registration form S-3. To satisfy the fifth *Cammer* factor, Plaintiff relies on an  
11 event study conducted by Coffman, which Plaintiff contends provides direct evidence that  
12 the price of Insys common stock promptly responded to the release of Insys-specific  
13 information during the Class Period.

14 As described by Coffman, “[a]n event study is a technique used to measure the effect  
15 of new information on the market prices of a company’s publicly traded securities.” (Doc.  
16 160-3 at 21.) “An event study is conducted by specifying a model of expected price  
17 movements conditioned on outside market factors and then testing whether the deviation  
18 from expected price movements is sufficiently large that simple random movement can be  
19 rejected as the cause.” *Id.* Coffman’s event study compared Insys’s stock price movements  
20 on 15 days when Insys released its earnings results (“news days”) to days when no news  
21 regarding Insys was released (“non-news days”). Coffman concluded that the Insys  
22 common stock price was far more likely to exhibit statistically significant price reaction on  
23 “news days” than on “non-news days.” In Coffman’s opinion, Insys common stock  
24 experienced a statistically significant price reaction at the 95% confidence level on 33.33%  
25 of the “news days,” compared to 2.60% of “non-news days.”

26 The Class Period is March 3, 2015, through January 25, 2016. Coffman determined  
27 that the Class Period consisting of 227 trading days was “not sufficiently long to provide  
28 enough data with which to test cause-and-effect in isolation.” (Doc. 160-3 at 25 n.61.)



1 Therefore, Coffman examined the price response of Insys common stock to 15 earnings  
2 announcements that occurred during the “Analysis Period,” which Coffman defined as four  
3 quarters before the Class Period through four quarters after the Class Period. (*Id.* at 25.)  
4 Only four of the 15 earnings announcements Coffman examined were issued during the  
5 Class Period. (*Id.*) Of the 15 earnings announcements issued during the Analysis Period,  
6 five resulted in statistically significant price movements above the 95% confidence level;  
7 only one of the five was issued during the Class Period. Coffman concluded that on five  
8 of the 15 (33.33%) “news days” Insys common stock experienced a statistically significant  
9 price movement. Coffman then examined the 154 “non-news days” during the Analysis  
10 Period and found four statistically significant price movements, which comprised 2.60%  
11 of the “non-news days.” He concluded that 33.33% is statistically significantly different  
12 from 2.60%.

13 To establish a presumption of reliance, Plaintiff must show that the market was  
14 efficient during the period for which the presumption of reliance is sought, *i.e.*, the Class  
15 Period. Plaintiff offers no basis for assuming that the market’s responsiveness a year before  
16 and a year after the Class Period is representative of the market’s responsiveness during  
17 the Class Period. A longer period for analysis is necessary only because there are too few  
18 events during the Class Period to draw statistical conclusions. During the Class Period,  
19 there were only four “news days,” and only one of those was associated with a statistically  
20 significant price reaction. However, even considering the entire Analysis Period, only one-  
21 third of the “news days” were associated with statistically significant price movements;  
22 two-thirds were not. Moreover, during the Analysis Period, there were nine days during  
23 which Insys common stock experienced a statistically significant price movement, five of  
24 which occurred on “news days” and four of which occurred on “non-news days.” And  
25 there were ten “news days” during which Insys common stock did not experience a  
26 statistically significant price movement. There are just too few “news days” to observe a  
27 meaningful correlation between “news” and “price reaction.”  
28

1 Further, Coffman characterized each of the days on which an earnings report was  
2 released as a “news day” regardless of whether the “news” was expected or unexpected,  
3 and he did not report regarding any “news” other than earnings reports. The fifth *Cammer*  
4 factor considers whether there is a correlation between *unexpected* public information and  
5 a change in a stock’s price; information that is consistent with expectations likely would  
6 not affect a stock’s price. Moreover, finding an association between “news” and “price  
7 reaction” does not demonstrate that “good news” correlated with price increases and “bad  
8 news” correlated with price decreases.

9 Defendants’ rebuttal expert, David C. Smith, Ph.D., was tasked with assessing  
10 whether Coffman had reliably demonstrated that the market for Insys common stock was  
11 efficient during the Class Period. Smith opined that finding market efficiency requires  
12 satisfaction of the fifth *Cammer* factor, regardless of evidence regarding other factors, and  
13 that flaws in Coffman’s methodology renders his analysis incapable of reliably assessing  
14 market efficiency of Insys common stock during the Class Period. Among other things,  
15 Smith contends that an efficient market responds rapidly to new, value-relevant  
16 information nearly 100% of the time and Coffman failed to assess the speed, size, and  
17 direction of the stock price response to “news.” Smith further contends Coffman failed to  
18 establish that what he characterized as “news” was in fact new, value-relevant information.  
19 Smith provides examples of varying and inconsistent returns to similarly positive  
20 unexpected information and similarly positive analyst commentary, demonstrating market  
21 inefficiency, that Coffman has not explained. Coffman responds to each of Smith’s  
22 criticisms and provides additional statistical analysis, but fails to overcome the fact that  
23 there were too few “news days” during the Class Period or the Analysis Period for  
24 statistical significance to have persuasive meaningful significance.

### 25 3. Additional Factors

26 Plaintiff provided evidence, which Defendants do not dispute, that additional factors  
27 support finding market efficiency in this case. Coffman, Plaintiff’s expert, reported that  
28

1 Insys's average market capitalization (\$2.2 billion) was greater than at least 68% of the  
2 companies whose securities traded on the NYSE and NASDAQ during the Class Period.

3 Regarding the bid-ask spread, Coffman explained that the narrower the bid-ask  
4 spread, the greater the indication of an efficient market. Coffman determined that the  
5 average bid-ask spread for Insys common stock during the Class Period was between  
6 0.12% and 0.36%, which was well below the average of 0.97% of a randomly selected  
7 group of 100 other common stocks on the NASDAQ.

8 Coffman reported that 280 institutions reported owning Insys common stock during  
9 the Class Period, holding on average 87.2% of public float. He opined that this substantial  
10 level of institutional ownership, coupled with the high trading volume, supports a  
11 conclusion of market efficiency.

12 Autocorrelation measures the relationship between a variable's current value and its  
13 past values. If past price movements of a security predict future price movements, the  
14 prices are said to be "autocorrelated." If autocorrelation is persistent and sufficiently large,  
15 a trader can consistently earn riskless profits over time, and the market is considered  
16 inefficient. Coffman's statistical analysis showed there was no evidence of autocorrelation  
17 for Insys common stock during the Class Period.

18 Finally, Coffman found considerable option trading in Insys common stock during  
19 the Class Period, which in Coffman's opinion supports finding that Insys common stock  
20 traded in an efficient market throughout the Class Period.

#### 21 **4. Market Efficiency Findings**

22 As explained above, there is no bright line test for determining market efficiency.  
23 Multiple factors are to be considered and do not necessarily deserve equal weight.  
24 Plaintiffs may prove market efficiency without satisfying the fifth *Cammer* factor. *See,*  
25 *e.g., Angley v. UTi Worldwide Inc.*, 311 F. Supp. 3d 1117, 1121 (C.D. Cal. 2018) (district  
26 court concluded it was not necessary to reach a conclusion regarding the fifth *Cammer*  
27 factor); *Petrie v. Electronic Game Card, Inc.*, 308 F.R.D. 336, 358 (C.D. Cal. 2015)  
28 (district court found that the plaintiffs had met their burden of proving that they were

1 entitled to the fraud-on-the-market presumption where plaintiffs had “relatively weak  
2 evidence of market efficiency” and “the most important cause-and-effect factor” weighed  
3 only weakly in favor of the plaintiffs); *Smilovits v. First Solar, Inc.*, 295 F.R.D. 423, 437  
4 (D. Ariz. 2013) (district court found that the plaintiffs had shown the stock traded on an  
5 efficient market by showing that three of the five *Cammer* factors were satisfied, another  
6 was partially satisfied, and the stock traded on the NASDAQ even though the evidence was  
7 “essentially a stand-off on the fifth *Cammer* factor”).

8 Here, Defendants do not dispute that four of the five *Cammer* factors, all of the  
9 *Krogman* factors, and several other factors are satisfied. Although the fifth *Cammer* factor  
10 is important, the scarcity of “news days” during the relevant period precludes meaningful  
11 statistical analysis. Concluding that under these circumstances it is not necessary to satisfy  
12 the fifth *Cammer* factor, the Court finds that Insys common stock traded in an efficient  
13 market throughout the Class Period.

14 Therefore, under *Basic*’s fraud-on-the-market theory, Plaintiff is entitled to a  
15 presumption of reliance based on indirect evidence of price impact unless Defendants  
16 produce “direct, more salient evidence showing that the alleged misrepresentation did not  
17 actually affect the stock’s market price and, consequently, that the *Basic* presumption does  
18 not apply.” *Halliburton II*, 573 U.S. at 282.

#### 19 **B. Defendants’ Rebuttal of the *Basic* Presumption**

20 Although plaintiffs do not need to directly prove price impact to invoke the *Basic*  
21 presumption, defendants may defeat the presumption at the class certification stage through  
22 direct evidence that the misrepresentation at issue did not *in fact* affect the stock price. *Id.*  
23 at 279, 282. “Any showing that severs the link between the alleged misrepresentation and  
24 either the price received (or paid) by the plaintiff, or his decision to trade at a fair market  
25 price, will be sufficient to rebut the presumption of reliance.” *Basic*, 485 U.S. at 248. “The  
26 Supreme Court provided a non-exhaustive list of ways that defendants can rebut the  
27 presumption, including by showing: (1) the market did not respond to the alleged  
28 misrepresentations; (2) the misrepresentations were immaterial; (3) a plaintiff did not

1 actually rely on the misrepresentations; or (4) a plaintiff would have sold the securities  
2 without relying on the integrity of the market.” *In re DVI, Inc. Sec. Litig.*, 639 F.3d 623,  
3 637 (3d Cir. 2011) (summarizing *Basic*, 485 U.S. at 248-49).

#### 4 **1. Burden of Proof for Rebuttal**

5 The parties dispute whether in order to successfully rebut the *Basic* presumption  
6 Defendants must demonstrate a lack of price impact by a preponderance of the evidence or  
7 merely meet a burden of production. Neither the Supreme Court nor the Ninth Circuit has  
8 expressly decided the question.

9 Federal Rule of Evidence 301 provides:

10 In a civil case, unless a federal statute or these rules provide otherwise,  
11 the party against whom a presumption is directed has the burden of producing  
12 evidence to rebut the presumption. But this rule does not shift the burden of  
13 persuasion, which remains on the party who had it originally.

14 The Advisory Committee’s Notes to Rule 301 (1974 Enactment) explain that the  
15 Committee adopted “an intermediate position under which a presumption does not vanish  
16 upon the introduction of contradicting evidence, and does not change the burden of  
17 persuasion; instead it is merely deemed sufficient evidence of the fact presumed, to be  
18 considered by the jury or other finder of fact.” The Notes further state:

19 If the adverse party offers no evidence contradicting the presumed fact, the  
20 court will instruct the jury that if it finds the basic facts, it may presume the  
21 existence of the presumed fact. If the adverse party does offer evidence  
22 contradicting the presumed fact, the court cannot instruct the jury that it may  
23 *presume* the existence of the presumed fact from proof of the basic facts. The  
24 court may, however, instruct the jury that it may infer the existence of the  
25 presumed fact from proof of the basic facts.

26 Applying Rule 301, therefore, if persuaded, the court as trier of fact may infer the existence  
27 of the presumed fact (*i.e.*, the *Basic* presumption of reliance) upon proof of the prerequisites  
28 for the *Basic* presumption even though the adverse party has produced contradicting  
evidence.

The Second Circuit has held that “defendants must rebut the *Basic* presumption by  
disproving reliance by a preponderance of the evidence at the class certification stage.”

1 *Waggoner v. Barclays PLC*, 875 F.3d 79, 99 (2d Cir. 2017); accord *Arkansas Teachers*  
2 *Ret. Sys. v. Goldman Sachs Group, Inc.*, 879 F.3d 474, 485 (2d Cir. 2018). In *Waggoner*,  
3 the Second Circuit rejected the defendants’ contention that Federal Rule of Evidence 301  
4 imposed a burden of production, not persuasion, for rebutting the *Basic* presumption. 875  
5 F.3d at 102-03. It reasoned that because the *Basic* presumption was adopted by the  
6 Supreme Court pursuant to federal securities laws and has been described by the Court as  
7 a substantive doctrine of federal securities fraud law, there is a sufficient link to satisfy  
8 Rule 301’s exception for federal statutory provisions. The Second Circuit did not explain  
9 exactly how federal securities law provides a rule other than Rule 301.

10 In *Waggoner*, the court did explain that it would be inconsistent with *Halliburton II*  
11 to require plaintiffs to prove satisfaction of the predominance requirement, including the  
12 prerequisites for invoking the *Basic* presumption of reliance, “while allowing defendants  
13 to rebut the *Basic* presumption by simply producing *some* evidence of market inefficiency,  
14 but not demonstrating its inefficiency to the district court. The presumption of reliance  
15 would also be of little value if it were so easily overcome.” 875 F.3d at 100-01. The court  
16 further found that the specific language of *Halliburton II* “demonstrates that the Court  
17 understood the burden that shifts to defendants as one of persuasion rather than  
18 production”:

19 [T]he majority in *Halliburton II* explained that evidence that satisfied the  
20 “severing the link” standard would rebut the *Basic* presumption because  
21 “the basis for finding that the fraud had been transmitted through market  
22 price would be gone,” and the defendants’ “direct, more salient evidence”  
that the misrepresentations did not affect the stock price would rebut the  
*Basic* presumption.

23 *Waggoner*, 875 F.3d at 101-02 (quoting *Halliburton II*, which quotes *Basic*). “If a  
24 defendant shows that an alleged misrepresentation did not, for whatever reason, actually  
25 affect the market price of defendant’s stock, there is no grounding for any contention that  
26 the investor indirectly relied on that misrepresentation through his reliance on the integrity  
27 of the market price.” *Arkansas Teachers*, 879 F.3d at 486.

28

1 In *Waggoner*, the Second Circuit also rejected the defendants' reliance on *IBEW*  
2 *Local 98 Pension Fund v. Best Buy Co.*, 818 F.3d 775 (8th Cir. 2016). 875 F.3d at 103  
3 n.36. In *Best Buy*, the Eighth Circuit quoted Rule 301 referring to "the burden of producing  
4 evidence to rebut the presumption" and stated, "[W]hen plaintiffs presented a *prima facie*  
5 case that the *Basic* presumption applies to their claims, defendants had the burden to come  
6 forward with evidence showing a lack of price impact." 818 F.3d at 782. The Second  
7 Circuit did not read *Best Buy* as deciding the extent of the burden of proof because it was  
8 not at issue and the Eighth Circuit described the rebuttal evidence as "overwhelming."  
9 *Waggoner*, 875 F.3d at 103 n.36.

10 Although Rule 301 provides an exception where "a federal statute or these rules  
11 provide otherwise," it is not necessary here to find that the *Basic* presumption of reliance  
12 is a substantive doctrine of federal securities fraud law that requires shifting the burden of  
13 persuasion to the party opposing the presumption. In this case, applying Rule 301's  
14 "intermediate position," the Court can infer the existence of the presumed fact (*i.e.*,  
15 reliance) from Plaintiff's proof based on indirect evidence of price impact because  
16 Defendants have not made "[a]ny showing that severs the link between the alleged  
17 misrepresentation and either the price received (or paid) by the plaintiff, or his decision to  
18 trade at a fair market price." *See Basic*, 485 U.S. at 248.

## 19 2. Rebuttal Evidence

20 Defendants contend they have rebutted any presumption of reliance "through direct,  
21 empirical evidence" because they have used Plaintiff's expert report to demonstrate that  
22 the two alleged misrepresentations at issue had no statistically significant impact. (Doc.  
23 165 at 16.) Defendants assert that the two statements were made on March 3, 2015, and  
24 that, based on Plaintiff's expert's analysis, there was not a statistically significant change  
25 in stock price on March 3, 2015, or March 4, 2015. (*Id.* at 17-18.) However, Plaintiff's  
26 failure to show a price reaction on March 3, 2015, or March 4, 2015, at the 95% confidence  
27 level is not direct, empirical evidence at the 95% confidence level of the *absence* of a price  
28 reaction. The *lack* of statistically significant proof that a statement affected the stock price



1 is not statistically significant proof of the opposite, *i.e.*, that it did *not* actually affect the  
2 stock price.

3 Defense expert Smith testified that he was not offering an opinion that the alleged  
4 misrepresentations had no impact on the price of Insys common stock. (Doc. 169-1 at  
5 5:18-23.) Rather, Smith opined that Coffman's analysis showed that there was no  
6 statistically significant stock price change on the dates of the two alleged  
7 misrepresentations. (*Id.* at 6:19-25.)

8 Moreover, Coffman's analysis did not assess the direct price impact of any specific  
9 statement. It focused on market efficiency based on earnings reports. Coffman reported  
10 that of the 15 earnings announcements Insys issued during the Analysis Period, only five  
11 resulted in statistically significant price movements above the 95% confidence level. (Doc.  
12 160-3 at 26.) Coffman explained:

13 In any event, even though we observe a number of statistically significant  
14 price movements, it is not at all unusual for earnings announcements to be  
15 accompanied by price movements that are not statistically significant (after  
16 all, requiring 95% confidence that a stock price movement was caused by  
17 information sets a high bar for evidence of cause and effect). This would  
18 happen, for instance, in quarters where there was not much surprise and the  
firm roughly met market expectations, if the firm offered little change in  
guidance, and/or if there was a mix of both positive and negative information  
that netted out.

19 (*Id.* at 26 n.65.)

20 Coffman also reported that on March 3, 2015, Insys issued a press release before  
21 market hours announcing 4Q 2014 earnings results and a few hours later held a conference  
22 call to discuss the earnings announcement. (Doc. 169-2 at 27.) Both the press release and  
23 conference call announced positive earnings surprises and negative results, including  
24 higher than anticipated legal fees and costs for research and development. (*Id.* at 27-28.)  
25 Market analysts were generally pleased with the company's performance, but factored the  
26 greater than expected costs into their forecasts. (*Id.* at 28-29.) Coffman's analysis found  
27 that on March 3, 2015, Insys common stock increased by 0.36% after controlling for market  
28

1 and industry effects, which is directionally consistent with the total mix of information  
2 released and analyst reaction, but is not statistically significant. (*Id.* at 30.)

3 Defendants have not produced evidence that severs the link between the alleged  
4 misrepresentations and the price paid or received by Plaintiff. They have not shown that  
5 the market *in fact* did not respond to the alleged misrepresentations. They have shown  
6 only that Plaintiff has not proved that it did, and Plaintiff is not required to do so at the  
7 class certification stage. Because Plaintiff has proved the basic facts required by *Basic*,  
8 and Defendants have not rebutted the *Basic* presumption of reliance, Plaintiff is entitled to  
9 a presumption of reliance.

### 10 C. The *Affiliated Ute* Presumption of Reliance

11 In addition to the fraud-on-the-market presumption of reliance, reliance also may be  
12 presumed in cases “involving primarily a failure to disclose” when the information  
13 withheld is “material in the sense that a reasonable investor might have considered them  
14 important in the making of this decision.” *Affiliated Ute Citizens v. United States*, 406 U.S.  
15 128, 153-54 (1972) (concluding sellers of stock had a right to know that the defendants  
16 who facilitated the sales would gain financially from the sales and that the stock was selling  
17 for a higher price in the market). However,

18 [S]ecurities laws do not create an affirmative duty to disclose any and all  
19 material information. Instead, companies can control what they have to  
20 disclose under these provisions by controlling what they say to the market.  
21 But once defendants choose to tout positive information to the market, they  
22 are bound to do so in a manner that wouldn’t mislead investors, including  
23 disclosing adverse information that cuts against the positive information.

24 *Schueneman v. Arena Pharmaceuticals, Inc.*, 840 F.3d 698, 705-06 (9th Cir. 2016) (quoting  
25 *Matrixx Initiatives, Inc. v. Siracusano*, 563 U.S. 27, 44-45 (2011) and *Berson v. Applied*  
26 *Signal Tech., Inc.*, 527 F.3d 982, 987 (9th Cir. 2008); citations, alterations, and internal  
27 quotation marks omitted).

28 The *Affiliated Ute* presumption of reliance is limited to cases that can be  
characterized as primarily alleging omissions. *Desai v. Deutsche Bank Sec. Ltd.*, 573 F.3d

1 931, 940 (9th Cir. 2009). Omissions “stem from the failure to disclose accurate information  
2 relating to the value of a security where one has a duty to disclose it.” *Id.*

3 Any fraudulent scheme requires some degree of concealment, both of the  
4 truth and of the scheme itself. We cannot allow the mere fact of this  
5 concealment to transform the alleged malfeasance into an omission rather  
6 than an affirmative act. To do otherwise would permit the *Affiliated Ute*  
7 presumption to swallow the reliance requirement almost completely.  
8 Moreover, it would fail to serve the *Affiliated Ute* presumption’s purpose  
9 since this is not a case where reliance would be difficult to prove because it  
10 was based on a negative.

11 *Id.* at 941 (quoting *Joseph v. Wiles*, 223 F.3d 1155, 1163 (10th Cir. 2000)). “[T]he  
12 *Affiliated Ute* presumption should not be applied to cases that allege both misstatements  
13 and omissions unless the case can be characterized as one that primarily alleges omissions.”  
14 *Binder v. Gillespie*, 184 F.3d 1059, 1064 (9th Cir. 1999).

15 Plaintiff contends that he is entitled to the *Affiliated Ute* presumption of reliance “at  
16 least with respect to those claims that rely primarily on omissions.” (Doc. 159 at 21.) He  
17 does not, however, identify which claims rely primarily on omissions. Nor does he identify  
18 what information Defendants had a duty to disclose.

19 The portions of the Second Amended Complaint that were not dismissed (Docs. 77,  
20 107) allege that, during a conference call with analysts, Defendant Babich said, “We keep  
21 hitting new highs in the number of new doctors that we activate on a weekly basis. We  
22 have some very unique programs within the oncology setting that we continue to execute  
23 on and any growth that we see in this overall TIRF class is specifically coming from  
24 Subsys.” (Doc. 77 at 103; *see* Doc. 107 at 41.) In addition, the FY14 Form 10-K stated  
25 that “some of the key factors in generating continued growth in Subsys usage include  
26 taking market share from other competing TIRF products and expanding the usage of  
27 Subsys for BTCP by building awareness among oncologists . . . .” (Doc. 77 at 105; *see*  
28 Doc. 107 at 41.)<sup>2</sup> The complaint alleges that these statements “were materially false and

---

<sup>2</sup> “TIRF” refers to “Transmucosal Immediate-Release Fentanyl.” “BTCP” refers to  
“breakthrough cancer pain.”

1 misleading when made or omitted material information such that they were rendered  
2 misleading.” (Doc. 77 at 105.) The complaint further alleges that Defendants knew or  
3 were deliberately reckless in disregarding that “new highs in the number of new doctors”  
4 and “continued growth in Subsys usage” were the result of illegal off-label promotion,  
5 illegal kickbacks to prescribers, and insurance fraud, not from “building awareness among  
6 oncologists.”

7 Presumably, reasonable investors would have considered information regarding  
8 illegal off-label promotion, illegal kickbacks to prescribers, and insurance fraud to be  
9 material. They likely would have considered material the information that Insys sales  
10 representatives were instructed to avoid meeting with oncologists and pain specialists and  
11 to aggressively pursue prescribers who did not have cancer patients. As alleged,  
12 Defendants had a duty to disclose this information because they touted inconsistent positive  
13 information to the market. But this case cannot be characterized as one that *primarily*  
14 alleges omissions. Therefore, the *Affiliated Ute* presumption of reliance does not apply  
15 here.

#### 16 **D. Plaintiff’s Damages Methodology**

17 “To prevail on the merits in a private securities fraud action, investors must  
18 demonstrate that the defendant’s deceptive conduct caused their claimed economic loss.”  
19 *Halliburton I*, 563 U.S. at 807. However, they are not required to prove loss causation at  
20 the class certification stage. *Id.* At the class certification stage, the plaintiffs need only  
21 present a workable method for calculating damages on a classwide basis that is consistent  
22 with their theory of liability.

23 Under Rule 23(b)(3), a plaintiff must show a classwide method for damages  
24 calculations as part of the assessment of whether common questions predominate over  
25 individual questions. *Lambert v. Nutraceutical Corp.*, 870 F.3d 1170, 1182 (9th Cir. 2017),  
26 *rev’d on other grounds*, 139 S. Ct. 710 (2019). “Uncertainty regarding class members’  
27 damages does not prevent certification of a class as long as a valid method has been  
28 proposed for calculating those damages.” *Id.* A plaintiff must present “a workable

1 method.” *Id.* at 1184. “Courts regularly reaffirm that the out-of-pocket, or event study,  
2 method matches plaintiffs’ theory of liability under Section 10(b) of the Securities  
3 Exchange Act, making it the standard method for calculating damages in virtually every  
4 Section 10(b) class action.” *City of Miami Gen. Employees’ & Sanitation Employees’ Ret.*  
5 *Trust v. RH, Inc.*, No. 17-CV-00554-YGR, 2018 WL 4931543, at \*3 (N.D. Cal. Oct. 11,  
6 2018) (collecting cases).

7 “[A]t the class-certification stage (as at trial), any model supporting a plaintiff’s  
8 damages case must be consistent with its liability case.” *Comcast Corp. v. Behrend*, 569  
9 U.S. 27, 35 (2013) (internal quotation marks and citation omitted). In *Comcast*, customers  
10 brought an antitrust class action against a cable television company and its subsidiaries  
11 based on the company’s strategy of acquiring competitor cable providers in a certain region  
12 in exchange for systems outside the region, which allegedly eliminated competition and  
13 held prices for cable services above competitive levels. *Id.* at 29-30. The plaintiffs  
14 proposed four theories of individual injury resulting from the alleged antitrust violation,  
15 but the district court accepted only one of the theories as capable of classwide proof. *Id.*  
16 at 31. The plaintiffs’ expert designed a regression model comparing actual cable prices in  
17 the region with hypothetical prices that would have prevailed but for the defendants’  
18 allegedly anticompetitive activities. The model assumed the validity of all four theories of  
19 alleged harm and did not isolate damages resulting from any one theory. *Id.* at 32, 36. In  
20 contrast, there is only one theory of liability here: “Plaintiff’s liability theory is ‘an inflated  
21 stock price as a result of certain misrepresentations and/or omissions’ and corrective  
22 disclosures that removed such inflation.” (Doc. 168 at 16.)

23 “[U]ncertain damages calculations do not alone defeat certification,” and  
24 “individualized damages issues do not alone defeat certification.” *Huu Nguyen v. Nissan*  
25 *N. Am., Inc.*, 932 F.3d 811, 817 (9th Cir. 2019). But plaintiffs must be able to show that  
26 their damages stemmed from the defendants’ actions that created the legal liability. They  
27 also must be able to show that damages are capable of measurement on a classwide basis,  
28 *i.e.*, the entire class suffered damages traceable to the same injurious actions underlying

1 the plaintiffs' legal theory. *Id.* In *Nguyen*, the plaintiff's legal theory was that the  
2 defendant knowingly designed a defective clutch system and did not inform consumers of  
3 the defect. *Id.* at 819. Under this theory, the defect existed in each of the class vehicles at  
4 the time of purchase and required remedy regardless of whether class members had  
5 experienced performance problems caused by the defect. Thus, the appropriate measure  
6 of damages was the benefit of the bargain and could be applied classwide. However, if the  
7 plaintiff had alleged that performance problems constituted the defect, class members  
8 might have received varying levels of compensation based on if and when they experienced  
9 performance problems. *Id.*

10 Defendants contend that Plaintiff has not satisfied Rule 23(b)(3)'s predominance  
11 requirement to proffer a methodology for calculating classwide damages that is consistent  
12 with his theory of liability. Coffman, Plaintiff's expert, opined that "damages in this action  
13 are subject to a well-settled, common methodology that can be applied to the class as a  
14 whole." (Doc. 160-3 at 36.) He stated:

15 [T]he standard and well-settled formula for assessing damages for each class  
16 member under Section 10(b) is the "out-of-pocket" method which measures  
17 damages as the artificial inflation per share at the time of purchase less the  
18 artificial inflation at the time of sale (or, if the share is not sold before full  
19 revelation of the fraud, the artificial inflation at the time of purchase, subject  
20 to the PSLRA's "90-day lookback" provision, a formulaic limit on damages  
21 that also can be applied class-wide).

22 . . . .

23 The methodology and evidence for establishing the artificial inflation per  
24 share in the market price on each day during the Class Period is also common  
25 to the class and can be measured class-wide. In particular, as is standard  
26 procedure in Section 10(b) cases, the most common methodology to quantify  
27 artificial inflation is to perform an event study that measures price reactions  
28 to disclosures that revealed the relevant truth concealed by the alleged  
material omissions and/or misrepresentations. This analysis, and the  
evidence supporting it, would be common to the class.

(*Id.* at 35.)

1 Defendants do not dispute that the standard “out-of-pocket” method and an event  
2 study are appropriate methods for determining damages in a securities fraud case. They  
3 do not contend that individual questions predominate. Rather, they contend that Coffman  
4 has not explained how his study would isolate the decline in Insys’s stock price that is  
5 allegedly attributable to the two misstatements at issue. Smith, Defendants’ expert, opined  
6 that Coffman’s anticipated “analysis will be insufficient to isolate only the price effect of  
7 the allegedly corrective information from other potentially confounding news that  
8 impacted the price of Insys stock but was not related to the allegations in this matter.”  
9 (Doc. 165-2 at 29-30.) As an example, Smith said that on December 3, 2015, an alleged  
10 corrective disclosure occurred and also Insys held an “investor day,” during which senior  
11 management provided information that investors would likely find relevant to the  
12 company’s stock price. Smith commented that Coffman had not addressed how he would  
13 separate the effect of the “investor day” news from that of the alleged corrective disclosure  
14 the same day. (*Id.* at 30.) Coffman responded:

15 81. Dr. Smith does not dispute that out-of-pocket damages in a  
16 class action pursuing claims under Section 10(b) of the Securities Exchange  
17 Act of 1934 can be computed based upon the artificial inflation in the stock  
18 price at the time of the purchase minus the artificial inflation at the time of  
19 sale (or just the inflation at the time of purchase if the share is not sold prior  
20 to revelation of the fraud).

21 82. Dr. Smith also does not dispute that the event study  
22 methodology is a reliable approach to isolate the price impact of new  
23 company-specific information for a given stock on a given day, and thus, to  
24 identify the potential inflation per share when corrective information is  
25 released.

26 83. Dr. Smith’s criticisms of my opinion on damages as expressed  
27 in the Coffman Report do not relate to whether the general out-of-pocket  
28 damages methodology can be applied formulaically in this matter using  
common proof on a class-wide basis. Instead, his objections all relate to  
whether certain adjustments would ultimately be necessary as a matter of loss  
causation *at the merits stage* to address (1) the purported release of putatively  
confounding information, if any, on the alleged corrective disclosure dates;  
and (2) how far back in time any inflation per share extends, i.e., when  
damages, and the Class Period, started. Answering these questions requires



1 a detailed loss causation analysis, which I understand is not required at this  
2 stage of the litigation, and, as a result, I have not been asked to perform.

3 84. These more detailed issues regarding loss causation (i.e.,  
4 “disaggregating” the effect of potential confounding information, whether in  
5 whole or in part, and how far back in time the inflation is to be carried) are  
6 regularly the subject of expert and merits discovery in securities class action  
7 matters, based upon a full factual record. Importantly for present purposes,  
8 however, the potential loss causation issues raised by Dr. Smith—if they are  
9 pertinent at all—may be determined based upon proof that is common to all  
10 class members.

11 85. To be clear, regardless of how the finder of fact ultimately  
12 weighs the evidence and determines the appropriate percentage of the  
13 abnormal stock price movement to be applied as artificial inflation resulting  
14 from the release of corrective versus any confounding information, that  
15 percentage can be mechanically incorporated into the standard damages  
16 model already identified using a common out-of-pocket formula. . . . In  
17 other words, regardless what the fact finder decides, the *methodology* for  
18 calculating damages will remain the same and apply equally to each class  
19 member.

20 (Doc. 169-2 at 43-44; footnotes omitted.)

21 Therefore, Plaintiff has proposed a method of calculating damages that is consistent  
22 with his theory of liability and can be applied classwide. At the class certification stage,  
23 he is not required to do more.

## 24 **V. SUMMARY**

25 Plaintiff has demonstrated compliance with Rule 23(a) of the Federal Rules of Civil  
26 Procedure, which Defendants do not dispute. Defendants also do not dispute that Plaintiff  
27 has satisfied the superiority requirement of Rule 23(b)(3). Regarding Rule 23(b)(3)’s  
28 requirement that questions common to class members predominate, Plaintiff has proved  
the prerequisites for invoking the fraud-on-the-market presumption of reliance under  
*Basic*, and Defendants have not rebutted it. The *Affiliated Ute* presumption of reliance  
does not apply because this case does not involve primarily a failure to disclose. Finally,  
Plaintiff has met his burden to propose a classwide method of calculating damages that is  
consistent with his theory of liability.

1 IT IS THEREFORE ORDERED that Defendants' Motion for Leave to File Sur-  
2 Reply in Further Opposition to Lead Plaintiff's Motion for Class Certification (Doc. 170)  
3 is granted. The Clerk will file the sur-reply attached as Exhibit A to the motion (Doc. 170-  
4 1).


5 IT IS FURTHER ORDERED that Lead Plaintiff's Motion for Class Certification  
6 (Doc. 159) is granted.

7 IT IS FURTHER ORDERED that this action is certified as a class action pursuant  
8 to Federal Rules of Civil Procedure 23(a) and 23(b)(3) on behalf of a Class consisting of  
9 all persons and entities who purchased or otherwise acquired Insys Therapeutics, Inc.,  
10 common stock during the period from March 3, 2015, through January 25, 2016, and were  
11 damaged thereby. Excluded from the Class are (a) Defendants; (b) present and former  
12 directors or executive officers of Insys and members of their immediate families (as defined  
13 in 17 C.F.R. § 229.404, Instructions (1)(a)(iii) and (1)(b)(ii)); (c) any of the foregoing  
14 individuals' or entities' legal representatives, heirs, successors, or assigns; and (d) any  
15 entity in which any Defendant has or had a controlling interest, or which is related to or  
16 affiliated with, any Defendant.

17 IT IS FURTHER ORDERED that Clark Miller is appointed as Class Representative.

18 IT IS FURTHER ORDERED that, pursuant to Federal Rule of Civil Procedure  
19 23(g), Kessler Topaz Meltzer & Check, LLP, is appointed as Class Counsel and Bonnett,  
20 Fairbourn, Friedman & Balint, P.C., is appointed as Liaison Counsel.

21 Dated this 20th day of September, 2019.

22  
23   
24 \_\_\_\_\_  
25 Neil V. Wake  
26 Senior United States District Judge  
27  
28